Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.37 (
DNA methyltransferase
)
4,983
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human breast cancer cells exhibit considerable diversity in the methylation status of genomic DNA CpGs that regulate metastatic transcriptome networks. In this study, we identified human
Sipa1
promoter-proximal elements that contained a CpG island and demonstrated that the methylation status of the CpG island was inversely correlated with
SIPA1
protein expression in cancer cells. 5-Aza-2'-deoxycytidine (5-Aza-CdR), a
DNA methyltransferase
inhibitor, promoted the expression of
Sipa1
in the MCF7 breast cancer cells with a low level of
SIPA1
expression. On the contrary, in MDA-MB-231 breast cancer cells with high
SIPA1
expression levels, hypermethylation of the CpG island negatively regulated the transcription of
Sipa1
In addition, the epithelial-mesenchymal transition (EMT) was reversed after knocking down
Sipa1
in MDA-MB-231 cells. However, the EMT was promoted in MCF7 cells with over-expression of
SIPA1
or treated with 5-Aza-CdR. Taken together, hypomethylation of the CpG island in
Sipa1
promoter-proximal elements could enhance
SIPA1
expression in breast cancer cells, which could facilitate EMT of cancer cells, possibly increasing a risk of cancer cell metastasis in individuals treated with 5-Aza-CdR.
...
PMID:5-Aza-2'-deoxycytidine advances the epithelial-mesenchymal transition of breast cancer cells by demethylating
Sipa1
promoter-proximal elements. 3219 33
